Austria-based Apeiron Biologics has acquired an option to license several cancer-treating drug candidates from Cleveland Clinic for an unspecified amount.
The drug candidates, which are designed to fight cancer based on stimulation of the immune system, have shown favorable results in animal testing, according to a statement from Apeiron.
“We regard the compounds developed at Cleveland Clinic as an attractive opportunity since they are designed to activate the patient’s own immune system,” said Apeiron CEO Hans Loibner.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Apeiron was founded in 2003 and licensed a respiratory drug to GlaxoSmithKline last year. GSK also acquired a minority stake in the company.
Privately held Apeiron has several other cancer drugs under development.
